Immunovant, Inc. (IMVT) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 New York City, NY, 美国. 現任CEO為 Eric Venker.
IMVT 擁有 IPO日期為 2019-06-21, 362 名全職員工, 在 NASDAQ Global Select, 市值為 $5.58B.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies to treat autoimmune diseases. The company's lead candidate, batoclimab, is a fully human monoclonal antibody that selectively inhibits the neonatal fragment crystallizable receptor and is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials recently initiated for warm autoimmune hemolytic anemia. Founded in 2018 and headquartered in New York, Immunovant operates as a subsidiary of Roivant Sciences Ltd.
